By Thomas Anderson, Rotem Petranker — 2018
We just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results.
Read on theconversation.com
CLEAR ALL
In the 1950s a group of pioneering psychiatrists showed that hallucinogenic drugs had therapeutic potential, but the research was halted as part of the backlash against the hippy counterculture.
Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.
The first randomized controlled trial to compare the illicit psychedelic psilocybin with a conventional selective serotonin reuptake inhibitor (SSRI) antidepressant found that the former improved symptoms of depression just as well on an established metric—and had fewer side effects.
1
Study participants at some of the country's leading medical research centers are going through intense therapy and six-hour psychedelic journeys deep into their minds to do things like quit smoking and worry less.
2
Once considered the quintessential party drug, MDMA (also known as “ecstasy,” “X,” or “molly”) is now experiencing a surge of interest in a completely different area: psychedelic-assisted psychotherapy.
LSD, or lysergic acid diethylamide, is a synthetic drug with potent psychedelic properties. Commonly known as acid, it was originally derived from compounds found in ergot, a fungus that grows on rye.
Psychedelic drugs are making a quiet comeback, as a smattering of recent studies have demonstrated their medicinal potential. The latest finding suggests it is time to revisit LSD as a treatment for addiction.
The drug lowers brain barriers, allowing distant regions to talk and thoughts to flow more freely.
The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).
As Western medicine brings psychedelics into mainstream use, a growing movement is innovating new business models grounded in reciprocity and inclusion.